Work

ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1-7) as a therapy for clear cell renal cell carcinoma

Year: 2021

Type: article

Source: Science Translational Medicine

DOI: 10.1126/scitranslmed.abc0170

Authors: Prateek Khanna, Hong Jie Soh, Chun-Hau Chen, Ruchi Saxena, Seema Amin, Maura Naughton, Patrick Neset Joslin, Andrew Moore, Ziad Bakouny, Carol O’Callaghan, Paul Catalano, Sabina Signoretti, Rana McKay, Toni K. Choueiri, Manoj Bhasin, Thomas Walther, Rupal S. Bhatt

Institutions: Mount Auburn Hospital, Beth Israel Deaconess Medical Center, Harvard University, University College Cork, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Universitätsmedizin Greifswald, Universität Greifswald

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Dana-Farber Cancer Institute, National Heart, Lung, and Blood Institute, National Cancer Institute, National Institute of Neurological Disorders and Stroke, NIH Clinical Center

Awards: G1093102984, G1273380608, Regulation of brain endothelial integrity by angiotensin receptors as treatment for cerebral malaria, G4825075930, Targeting the compromised brain endothelial barrier function during cerebral malaria with AT2 receptor agonists, G8667473375

OpenAlex ID: W3122697193

FWCI: 5.37

Cites: 46

Cited by: 48

Related to: 10